Edition:
United Kingdom

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

13.20USD
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
$13.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
73,504
52-wk High
$14.90
52-wk Low
$5.35

Chart for

About

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads... (more)

Overall

Beta: -0.59
Market Cap(Mil.): $173.02
Shares Outstanding(Mil.): 28.13
Dividend: --
Yield (%): --

Financials

  CTSO.OQ Industry Sector
P/E (TTM): -- 148.68 32.76
EPS (TTM): -0.37 -- --
ROI: -77.87 9.38 14.61
ROE: -162.40 14.71 16.33

BRIEF-Cytosorb Adds Bilirubin And Myoglobin Reduction To Eu Approved Indications For Use

* CYTOSORB® ADDS BILIRUBIN AND MYOGLOBIN REDUCTION TO EUROPEAN UNION APPROVED INDICATIONS FOR USE

14 May 2018

BRIEF-CytoSorbents Reports Qtrly Loss Per Share $0.10

* CYTOSORBENTS REPORTS STRONG FIRST QUARTER 2018 FINANCIAL RESULTS

08 May 2018

BRIEF-Cytosorbents Enrolls First Patient Into Pivotal U.S. Refresh 2-AKI Trial

* CYTOSORBENTS ENROLLS FIRST PATIENT INTO PIVOTAL U.S. REFRESH 2-AKI TRIAL USING CYTOSORB® DURING COMPLEX CARDIAC SURGERY Source text for Eikon: Further company coverage:

24 Apr 2018

BRIEF-Cytosorbents Refinances Existing Debt With New $15 Mln Debt Facility With Bridge Bank

* CYTOSORBENTS REFINANCES EXISTING DEBT WITH NEW $15 MILLION DEBT FACILITY WITH BRIDGE BANK

04 Apr 2018

Competitors

Earnings vs. Estimates